



CITTA' DI
REGGIO CALABRIA



Associazione Italiana
Radioterapia e Oncologia clinica



SERVIZIO
REGIONALE
SALUTE
AZIENDA SANITARIA
PROVINCIALE
REGGIO CALABRIA



First international
congress of

BIOIMMUNOTHERAPY OF CANCER

An International multidisciplinary meeting

Responsabile Scientifico:

Dr. Pierpaolo Correale

12-13-14
APRILE 2019

REGGIO CALABRIA
ITALY

Palazzo della Provincia, Sala Perri, Piazza Italia,
89125 Reggio Calabria

April, FRIDAY 12th, 2019

Ore 8.30 Authority salutation

Vice-Ministro dell'economia, *Onorevole Senatore Massimo Garavaglia*
Autorità regionali
Autorità Città Metropolitana
Direzione Strategica Grande ospedale Metropolitano
Associazione Salus Donna: *Anna Mancuso*
Associazione ARCO: *Francesco Provenzano*

Ore 9.30 INTRODUCTION:

*Prof. Angelo Raffaele Bianco, Prof. Luigi Pirtoli, Prof. Pierosandro Tagliaferri,
Dr. Pierpaolo Correale*

GENERAL SESSION

STANDARD CARE AND PATIENT MANAGEMENT

(Lingua ufficiale Italiano):

CHAIRMEN: *Mario Roselli and Sabino de Placido*

Ore 9.45 / *Ettore Jorio*

Interrelazione ospedale territorio

Ore 10.00 / *Fiorella Guadagni*

Dalle Banche dati alla pratica clinica

Ore 10.15 / *Claudio Verusio*

Il passo dalla diagnosi alla presa in carico della "persona" paziente

Ore 10.30 / *Pierpaolo Correale*

Real World Evidence in Oncologia

Ore 10.45 / *Salvatore Palazzo*

Sostenibilità dei nuovi trattamenti, reperimento e razionalizzazione delle risorse

Ore 11.00 / *Giovanna Chiappetta*

Il consenso informato: tutela del paziente o difesa del medico

Ore 11.15 / *Antonio Giordano*

Le collaborazioni internazionali; formazione e leadership

Ore 11.30 / *Stefano Magrini*

Riorganizzazione della rete radioterapica regionale

Ore 11.45 / *Giovanna Malara*

Un modello di integrazione multi-disciplinare complessa nella diagnosi e cura del melanoma maligno; target therapy e immunocheckpoint

Ore 12.00 / *Rocco Giannicola*

Organizzazione, attrezzatura e necessità irrinunciabili per la creazione di una lung unit efficiente

Ore 12.15 / *Antonio Santo*

Una forza nazionale integrata contro il carcinoma polmonare

Ore 12.45 / *Guido Francini*

L'Oncologia nel paziente anziano

Ore 13.00 / *Maria Angela Polifrone*

La valutazione psiconcologica del paziente con carcinoma polmonare

LUNCH

Bio-immunotherapy congress

(Lingua ufficiale Inglese):

WORK OPENING: *Luigi Pirtoli, Pierosandro Tagliaferri, Pierpaolo Correale*

I SESSION

ADVANCEMENT FOR GENITOURINARY MALIGNANCIES

CHAIRMEN: *A Madan Ravi, Guido Francini*

Ore 15.00 / *Francesco Grillone*

Hormonal therapy evolution in prostate cancer

Ore 15.15 / *Edoardo Francini*

Role of chemotherapy in prostate cancer

Ore 15.30 / *Paolo Tini*

Salvage radiotherapy for prostate cancer; potential predictive immunological parameters of response

Ore 15.45 / *Camillo Porta*

Kidney Cancer molecular definition, inheritance and treatment implications

Ore 16.00 / *Giacomo Carteni*

TKI, mTOR inhibitors and anti-angiogenic mAbs in kidney cancer

Ore 16.15 / Rita Agostino

Kidney cancer a long lasting model for cancer immunotherapy: from the interleukin 2 to the immune-check point inhibitors

Ore 16.30 / Antonino Mafodda

Chemotherapy or immune-check point blockade in the savage treatment of metastatic urological malignancies

II Active specific Immunotherapy and immune-checkpoint inhibitors in Malignant melanoma, and Head and Neck Carcinoma (HNC)

CHAIRMEN: *Stefano Magrini*

Ore 17.00 / Grazia Cusi

Viral infections and HNC: Risks and perspectives

Ore 17.15 / Marta Maddalo

Combined treatments for locally advanced head and neck cancer: the changing role of cetuximab and the new research avenues

Ore 17.30 / Michele Del Vecchio

Development of Target therapy in the treatment of malignant melanoma

Ore 17.45 / Paola Queirolo

Immuno-check point inhibitors in the treatment of malignant melanoma: the state of art

Ore 18.00 / Paolo Pedrazzoli

Vaccine and adoptive therapy in HNC

Ore 18.15 / Rita Chiari

New targets for non small cell lung cancer

Ore 18.30 / Carmen Tebala

Radiological evaluation of Head and neck cancer and malignant melanoma patients receiving Immunological treatments

Conclusions of the day

Ore 20.30 DINNER

April, SATURDAY 13th, 2019

III Immuno-oncological development and controversies (III)

CHAIRMEN: *Jay Berzowsky*

Ore 8.30 / *M. Sitkovsky*

Critical role of hypoxia and cancer associated inflammation

Ore 8.45 / *Robert M Hoffman*

Animal models and immunolo-oncological research

Ore 9.00 / *Jack Greiner*

Basic principles of immunotherapy, cancer vaccines, co-accessory molecules

Ore 9.15 / *Jay Berzowsky*

Active specific immunotherapy Translation from mice to human clinical trials

Ore 9.30 / *A. Madan Ravi*

Immuno-oncological treatments for prostate carcinoma future directions

Ore 9.45 / *Massimo Di Maio*

History and clinical development of therapeutic immune-checkpoint blockades; future challenges

Ore 10.00 / *Vincenzo Desiderio*

Endoplasmic stress as a new target for anticancer therapies and immunological treatments

Ore 10.15 / *Fabio Malavasi*

Interplay between Fc domain of therapeutic antibodies and specific receptors on different effector populations

Ore 10.30 / *Claudio Tripodo*

Mechanism of failure of immune-checkpoints: effector failure or tumor resistance

Ore 10.45 / *K kosmatopoulos*

There still a role for cancer vaccine?

Ore 11.00 / *Bruno Cadilha*

Chemokine receptors enable adoptive T cell therapy homing into solid tumors

Ore 11.15 / *Sonia Quarantino*

Immunomodulation in cancer beyond PD-1 and PD-L1

Ore 11.30 / *Takuia Tsunoda*

The new generations of immunecheckpoint inhibitors

Ore 11.45 / *Pierpaolo Correale*

PD-1 blockade: Antigen cascade, Autoimmunity and Major Histocompatibility Complex -

COFFEE BREAK

IV Immuno-oncological development and controversies (neoantigens, immunopriming and monoclonal antibodies)

CHAIRMEN: *Kwong Yok Tsang and Fabio Malavasi*

Ore 12.00 / *Pierfrancesco Tassone*

Targeting a Specific Glycosylated Epitope of CD43 with a New Humanized Monoclonal Antibody for the Treatment of Human Malignancies

Ore 12.15 / *Kwong Yok Tsang*

Mechanisms of action of a neoantigen-targeting antibody NEO-201

Ore 12.30 / *Alfredo Colombo*

ADCC : from bench to bedside

Ore 12.45 / *Massimo Fantini*

An IL-15 superagonist, ALT-803 enhances antibody-dependent cell-mediated cytotoxicity (ADCC) elicited by the novel monoclonal antibody NEO-201 against human carcinoma cells

Ore 13.00 / *Christina Messineo Annunziata*

Immunotherapy in the treatment of gynecological malignancies

Ore 13.15 / *Caterina Alati*

New moAbs in the treatment of acute leukemia

Ore 13.30 / *Phil Arlen*

New antibodies in the treatment of bilio-pancreatic cancer

Ore 13.45 LUNCH

V Lung Cancer

CHAIRMEN: *Piero Paladini, Baldo Mondello*

Ore 14.30 / *Luca Luzzi*

Role of surgery and combined approach: neoadjuvant chemoradiotherapy and radio-immunotherapy

Ore 15.00 / *Marta Castiglia*

Liquid biopsy and precision medicine

Ore 15.15 / Nadia Pasinetti

Target therapy on drivers mutations

Ore 15.30 / Roberto Bianco

Targeting EGFR pathway as treatment of non small cell lung cancer

Ore 16.00 / Vito Barbieri

The Advent of immunotherapy from now to the future

Ore 16.15 / Rocco Giannicola

Care and monitoring of NSCLC patient in treatment with immune-checkpoint blockade: iRAEs Pain, Emesis, Infection, and quality of life

Ore 16.30 / Pierpaolo Pastina

Radiotherapy, new perspective and immunobiological effects

Ore 16.45 / Valerio Nardone

Immune-checkpoint blockade Response evaluation by Digital analysis

Ore 17.00 / Luca Volterrani

Radiological and clinical evaluation of Lung Cancer patients treated with immunotherapy or target therapy

VI Immuno-oncological development and controversies on adoptive therapy and micro RNA

CHAIRMEN: *Massimo Martino and Bruno Martino*

Ore 17.15 / Massimo Martino

Donor lymphocyte infusions in AML and MDS?

Ore 17.30 / Giulia Pucci

Processing CSE toward Jacie accreditation

Ore 17.45 / Patrizia Comoli

T cell therapy for viral infections

Ore 18.00 / Ciro Botta

Immunobiological characterization of Tumor infiltrating lymphocytes derived from multiple myeloma patients

Ore 18.15 / *Marco Rossi*

Car-T based immunotherapy and adoptive therapy

Ore 18.30 / *Michele Caraglia*

Micro-RNAs and long non coding RNAs loops in human cancers: a new deal in anti-cancer treatment and immunotherapy

Take the message round table

DISCUSSION LEADERS: *Chairmen: Massimo Martino and Bruno Martino*

April, SUNDAY 14th, 2019

VII Advancement in Gastro-enteric malignancies

CHAIRMEN: *Antonio Russo, Gianfranco Filippelli*

Ore 9.00 / *Candida Mastroianni*

Anti-angiogenic treatments in gastro-enteric malignancies

Ore 9.15 / *Martinelli Erika*

Ore 9.30 / *Pierpaolo Pastina*

Effects of inflammatory status and k-ras mutation on patients response to the thymidylate synthase poly-epitope peptide vaccin

Ore 9.45 / *Teresa Troiani*

Immune-check point blockade and EGFR inhibition in advanced colorectal cancer; present and future directions

Ore 10.00 / *Pierosandro Tagliaferri*

Chemo-immunotherapy of Colorectal cancer; fifteen years of GOLFIG experience

VIII session – Advancement in gynecological malignancies and breast cancer

CHAIRMEN: *Sandro Pignata and Serafino Conforti*

Ore 10.15 / *Stefano Palomba*

Surgery and combined therapeutic approaches to ovary and endometrial cancer

Ore 10.30 / *Sandro Pignata*

From the anti-blastic drugs to PARP inhibitor

Ore 10.45 / *Pietro del Medico*

Chemo-immunological treatments of gynaecological malignancies

Ore 11.00 / *Paolo Vigneri*

New pathways for breast cancer treatment; from bench to the bedside and vice-versa

Ore 11.15 / *Salvatore Vaccarella*

Il ruolo della medicina di precisione nella pratica oncologica

Ore 11.30 / *Carmelo Tuscano*

Radiotherapy and Cervical carcinoma, role of integrated treatments

Ore 11.45 / *Roberto Maisano*

The unstoppable advent of cycline inhibitors

Ore 12.00 / *Francesca Di Rella*

NPDL-1 blockade in the treatment of triple negative breast cancer

Ore 12.15 / *Michele Caruso*

The new directions of cycline inhibitors

Congress conclusions and salutations:

Michail Sitkovsky, Pierosandro Tagliaferri, Pierpaolo Correale

First international congress of **Bioimmunotherapy of Cancer**

An International multidisciplinary meeting

12-13-14 APRILE 2019 | REGGIO CALABRIA, ITALY

Responsabile Scientifico: **Dr. Pierpaolo Correale**

Il convegno è stato accreditato su Agenas, ha ottenuto i seguenti crediti formativi:

12 Aprile 2019 id 5090 - 253291 crediti assegnati N. **4.9**

13 Aprile 2019 id 5090- 253313 crediti assegnati N. **6.3**

14 Aprile 2019 id 5090- 253324 crediti assegnati N. **2.1**

Il convegno e' rivolto a N. **150** partecipanti PROVENIENZA REGIONALE

PROFESSIONE: MEDICO CHIRURGO

Discipline in: Allergologia ed immunologia clinica; anatomia patologica; chirurgia generale; chirurgia toracica; dermatologia e venereologia; ematologia; genetica medica; medicina generale (*medici di famiglia*); medicina interna; oncologia; radioterapia; urologia.

PROFESSIONE: INFERMIERE

Discipline in: Infermiere

PROFESSIONE: BIOLOGO

discipline in: Biologo

PROFESSIONE: FARMACISTA

discipline in: Farmacia ospedaliera; farmacia territoriale;

Tipologia evento: CORSO DI AGGIORNAMENTO

Obiettivi dell'Evento: LINEE GUIDA - PROTOCOLLI - PROCEDURE

CORSO GRATUITO

L'iscrizione è gratuita e può essere effettuata tramite e-mail all'indirizzo: xeniaeventi@gmail.com, allegando i dati anagrafici o telefonare al numero **0984.444890**

PROVIDER E SEGRETERIA ORGANIZZATIVA



XENIA

WE DEVELOP YOUR IDEAS

Xenia S.a.s. di Francesca Mazza & C.

Via G. Verdi, 144 - 87036 Rende CS

Tel. **0984 444 890** - Cell. **3441872101**

E-mail: xeniaeventi@gmail.com | Id Provider **5090**

Patrocinio concesso da



L' Iniziativa è stata realizzata grazie al supporto incondizionato di:



Bristol-Myers Squibb

